Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset (PROST-3)

11. listopadu 2026 aktualizováno: Tasly Biopharmaceuticals Co., Ltd.

A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset

This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Study Design: This is a multicenter, randomized, double-blind, double-dummy, standard-of-care (SOC)-controlled Phase III trial conducted at multiple centers in China. Randomization is performed using a stratified block randomization method, stratified by planned mechanical thrombectomy (2 levels: yes; no), with participants assigned in a 1:1 ratio to the rhPro-UK group or the SOC group.Treatment: Eligible and randomized participants receive the assigned investigational product as soon as possible (actual treatment initiation must be >4.5 hours and <=24 hours after stroke onset). The rhPro-UK group receives an intravenous infusion of rhPro-UK 35 mg in normal saline (15 mg as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg by intravenous infusion/pump over 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg at the start of thrombolysis. The SOC group receives an intravenous infusion of rhPro-UK placebo (same regimen) plus oral aspirin enteric-coated tablets 100-300 mg. All investigational products are administered once only; subsequent clinical antiplatelet therapy should be initiated no earlier than 24 hours after completion of the investigational product administration.Study Duration: The total duration of participation for each participant is approximately 90 days, including a screening period (pre-thrombolysis, -24 hours to 0 hour), a treatment period (thrombolysis, 0 hour), and a follow-up period (24 hours, 72 hours, Day 7, Day 30, and Day 90 after the start of thrombolysis).Statistical Considerations: The study hypothesis is based on the primary estimand. Null hypothesis H0: p1/p2 <= 1; alternative hypothesis H1: p1/p2 > 1, where p1 is the proportion of participants with an mRS score of 0-1 at 90 days in the rhPro-UK group and p2 is that in the SOC group. One interim analysis is planned, using the Lan-DeMets spending function with O'Brien-Fleming efficacy boundaries; the two-sided type I error is controlled at 0.003 for the interim analysis and 0.049 for the final analysis, maintaining an overall two-sided type I error of 0.05.Committees: An Academic Committee will be established before trial initiation to ensure the scientific feasibility of the protocol and standardization of trial conduct. An independent Clinical Events Committee (CEC) will adjudicate the type and drug-relatedness of all-cause death events within 7 days after treatment, as well as symptomatic intracranial hemorrhage (sICH). A Data Monitoring Committee (DMC) will convene regularly or as needed to perform unblinded sample size re-estimation, review safety data, and advise the sponsor on whether to continue, suspend, or stop the trial, or adjust the sample size.

Typ studie

Intervenční

Zápis (Odhadovaný)

978

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína
        • Beijing Tiantan Hospital, Capital Medical University
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Age >=18 years, male or female;
  2. Time from stroke symptom onset to planned thrombolysis >4.5 hours and <=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well;
  3. Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke;
  4. Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume <70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL);
  5. NIHSS score of 6 to 25 (inclusive);
  6. Pre-stroke mRS score <2;
  7. No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator);
  8. The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the informed consent form.

Exclusion Criteria:

  1. Unable to complete CTP/CTA or PWI/DWI/MRA examination;
  2. Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory);
  3. Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.);
  4. Previous history of intracranial hemorrhage;
  5. Major head trauma or ischemic stroke within the past 3 months;
  6. Intracranial tumor or giant intracranial aneurysm;
  7. Intracranial or intraspinal surgery within the past 3 months;
  8. Gastrointestinal or urinary tract bleeding within the past 3 weeks;
  9. Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator);
  10. Arterial puncture at a non-compressible site within the past 1 week;
  11. Active internal bleeding;
  12. Aortic arch dissection;
  13. Bacterial endocarditis or pericarditis;
  14. Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg;
  15. Acute bleeding tendency, including platelet count <100 x 10^9/L;
  16. Treatment with low-molecular-weight heparin or heparin within 24 hours;
  17. Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours;
  18. Currently taking oral anticoagulants with prothrombin time (PT) >15 seconds or international normalized ratio (INR) >1.7;
  19. Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance;
  20. Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL);
  21. Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis;
  22. Severe renal insufficiency (eGFR <30 mL/min/1.73 m^2);
  23. Any terminal illness with a life expectancy of less than 1 year;
  24. Known hypersensitivity to rhPro-UK, the active ingredient of aspirin, or any other components of the investigational products;
  25. Pregnant or lactating women;
  26. Participation in another clinical trial within the past 1 month;
  27. Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial;

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: rhPro-UK Group

Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

rhPro-UK 35 mg dissolved in normal saline, administered intravenously as a single dose: 15 mg slow intravenous bolus over 3 minutes, followed by 20 mg intravenous infusion/pump over 30 minutes. Treatment initiation must be >4.5 hours and <=24 hours after stroke onset.

Oral placebo matching aspirin enteric-coated tablets, 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion).

Aktivní komparátor: Standard of Care (SOC) Group

Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

Oral aspirin enteric-coated tablets 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). Subsequent clinical antiplatelet therapy is initiated no earlier than 24 hours after completion of the investigational product administration.

Placebo matching rhPro-UK for injection, dissolved in normal saline and administered intravenously with the same regimen as rhPro-UK (15 mg-equivalent slow intravenous bolus over 3 minutes, followed by 20 mg-equivalent intravenous infusion/pump over 30 minutes), single dose.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of Participants Achieving a Favorable Functional Outcome (mRS 0-1)
Časové okno: 90 days after treatment

Description: Proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment.

90 days after treatment

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Distribution of mRS Scores
Časové okno: 90 days after treatment

Distribution of modified Rankin Scale (mRS) scores at 90 days after treatment

90 days after treatment
Proportion of Participants Achieving Functional Independence (mRS 0-2)
Časové okno: 90 days after treatment

Proportion of participants with an mRS score of 0-2 at 90 days after treatment.

90 days after treatment
Proportion of Participants With Early Neurological Improvement at 24 Hours
Časové okno: 24 hours after treatment

Proportion of participants with a decrease of >=4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline, or an NIHSS score <=1, at 24 hours after treatment.

24 hours after treatment
Proportion of Participants With Neurological Improvement at Day 7
Časové okno: 7 days after treatment

Proportion of participants with a decrease of >=4 points in NIHSS score from baseline, or an NIHSS score <=1, at 7 days after treatment.

7 days after treatment
Change From Baseline in NIHSS Score at 24 Hours
Časové okno: Baseline and 24 hours after treatment

Change in NIHSS score from baseline at 24 hours after treatment.

Baseline and 24 hours after treatment
Change From Baseline in NIHSS Score at Day 7
Časové okno: Baseline and 7 days after treatment

Change in NIHSS score from baseline at 7 days after treatment.

Baseline and 7 days after treatment
Proportion of Participants With a Barthel Index of 95-100
Časové okno: 90 days after treatment

Proportion of participants with a Barthel Index score of 95-100 at 90 days after treatment.

90 days after treatment
Proportion of Participants Achieving Reperfusion at 24 Hours
Časové okno: 24 hours after treatment

Proportion of participants achieving reperfusion at 24 hours after treatment, defined as a >90% reduction from baseline in the volume of tissue with tracer arrival time (Tmax) >6 seconds.

24 hours after treatment
Proportion of Participants Achieving Good Reperfusion on Angiography Before Thrombectomy
Časové okno: Before mechanical thrombectomy (Day 0)

Proportion of participants achieving good reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) grade of 2b50 or higher, on angiography before thrombectomy (assessed only in participants undergoing mechanical thrombectomy).

Before mechanical thrombectomy (Day 0)
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the SITS-MOST Definition
Časové okno: Within 36 hours after treatment

Incidence of symptomatic intracranial hemorrhage as defined by the SITS-MOST criteria.

Within 36 hours after treatment
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the ECASS III Definition
Časové okno: Within 7 days after treatment

Incidence of symptomatic intracranial hemorrhage as defined by the ECASS III criteria.

Within 7 days after treatment
Incidence of All-Cause Mortality Within 7 Days
Časové okno: Within 7 days after treatment

Incidence of death from any cause within 7 days after treatment.

Within 7 days after treatment
Incidence of All-Cause Mortality Within 90 Days
Časové okno: Within 90 days after treatment
Within 90 days after treatment
Incidence of Major Bleeding Events Within 7 Days
Časové okno: Within 7 days after treatment
Within 7 days after treatment
Incidence of Intracranial Hemorrhage Events Within 7 Days
Časové okno: Within 7 days after treatment

Within 7 days after treatment

Within 7 days after treatment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

30. listopadu 2026

Primární dokončení (Odhadovaný)

1. března 2029

Dokončení studie (Odhadovaný)

1. června 2029

Termíny zápisu do studia

První předloženo

11. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

11. listopadu 2026

První zveřejněno (Aktuální)

17. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

17. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

11. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • TSL-BIO2601-AIS24-Ⅲ
  • NMPA IND No. (Jiný identifikátor: 2026LP02152)

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .